Figure 3From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus Mean remogliflozin (active entity) concentration (and standard deviation) vs. time profiles with and without metformin, n = 13. Back to article page